Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04263831 · ClinicalTrials.gov registry record · Phase 1
Low Dose IL-2 for the Treatment of Crohn's Disease
A Phase 1 study of Crohn Disease, sponsored by Boston Children's Hospital.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 3
- Study locations
NCT04263831 is a Phase 1 study of Crohn Disease that is actively recruiting participants, run by Boston Children's Hospital. The registered enrollment target is 30 participants, below the 205-participant average among 71 other Crohn Disease trials with a reported enrollment target (85% lower). The trial reports 3 study locations across 2 states.
The verdict
NCT04263831, a Phase 1 study of Crohn Disease, is actively recruiting participants, sponsored by Boston Children's Hospital.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this study is to determine the safety and maximum effective dose (MED) of Interleukin-2 in subjects with moderate-to-severe crohn's disease.
Conditions Studied
Interventions
- DRUG Interleukin-2 (aldesleukin).
Study Locations (3)
Massachusetts
- Boston Children's Hospital - Boston
- Brigham and Women's Hospital - Boston
New York
- Mount Sinai - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2021-03-11 |
| Est. Completion | 2027-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04263831
The ClinicalTrials.gov registry entry for NCT04263831 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 205-participant average among 71 other Crohn Disease trials with a reported enrollment target (85% lower). The listed sponsor is Boston Children's Hospital, which has 462 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Crohn Disease appearing as the primary indexed condition, and to 1 intervention - of which Interleukin-2 (aldesleukin). is the first listed.
NCT04263831 reports 3 study locations spanning 2 distinct geographic areas - top geographies include Massachusetts, New York.
Frequently Asked Questions
What is clinical trial NCT04263831 about?
NCT04263831 is a clinical study titled "Low Dose IL-2 for the Treatment of Crohn's Disease". The purpose of this study is to determine the safety and maximum effective dose (MED) of Interleukin-2 in subjects with moderate-to-severe crohn's disease.
What is the current status of trial NCT04263831?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2021-03-11. Estimated completion is 2027-12-31.
What conditions does trial NCT04263831 study?
This clinical trial studies the following conditions: Crohn Disease.
What interventions are being tested in trial NCT04263831?
The interventions under investigation include: Interleukin-2 (aldesleukin). (DRUG).
Who is sponsoring clinical trial NCT04263831?
This trial is sponsored by Boston Children's Hospital, which has 462 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04263831 being conducted?
This trial has 3 study locations across Massachusetts, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Crohn Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
RECRUITING · Phase 1
-
Stem Cell Transplantation in Crohn's Disease
RECRUITING · Phase 1
-
Pilot and Feasibility Study of 2'-FL as a Dietary Supplement in IBD Patients Receiving Stable Maintenance Anti-TNF Therapy
RECRUITING · Phase 1
-
Safety and Efficacy of EcoActive on Intestinal Adherent Invasive E. Coli in Patients With Inactive Crohn's Disease
ACTIVE NOT RECRUITING · Phase 1
-
A Randomized, Double-blind, Study to Explore the Effect of GED-0301 in Subjects With Active Crohn's Disease
COMPLETED · Phase 1
-
Fecal Microbiota Transplant (FMT) in Pediatric Active Ulcerative Colitis and Pediatric Active Crohn's Colitis
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.